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Objectives. The purpose of this study was to investigate lipopro-
tein(a) [Lp(a)] levels and apolipoprotein(a) [apo(a)] phenotypes
in relation to age of onset of coronary heart disease (CHD).
Background. Although Lp(a) levels have been extensively ana-
lyzed in relation to age of CHD, apo(a) phenotypes have not.
Methods. Three hundred and thirty-five consecutive CHD pa-
tients were enrolled and grouped according to their age of CHD
onset (<45 years; 45 to 54 years; >255 years).
Results. In each patient group Lp(a) levels were higher than in
an age-matched control group, but among the patient groups no
differences in Lp(a) levels were observed. Apolipoprotein(a) phe-
notype distributions showed significant differences between pa-
tients and age-matched control subjects. Among the patient
groups the difference in percentage of subjects with two apo(a)
isoforms of low molecular weight (MW) was highly significant
(p < 0.001). Multivariate analysis showed that apo(a) phenotypes
were the best predictors of early CHD (p < 0.000001). The
age-specific odds ratios (ORs) of the presence of at least one
apo(a) isoform of low MW for CHD declined with age; in
particular apo(a) phenotypes had their highest predictive value in
younger persons (OR: 14.62). The OR for the presence of two
isoforms of low MW/presence of only isoforms of high MW was
40.88 in the younger age group, 27.17 in age group of 45 to 54 years
and 15.83 in the older age group.
Conclusions. The present article reports the first evidence of a
strong independent association of apo(a) phenotypes with the age
of onset of CHD. Thus, if our data are confirmed by larger studies,
apo(a) phenotypes might be used together with Lp(a) levels as
powerful genetic markers in assessing the actual risk of develop-
ing CHD at a young age.
(J Am Coll Cardiol 1999;33:157–63)
©1998 by the American College of Cardiology
Lipoprotein(a) [Lp(a)] represents a plasma lipoprotein, which
is similar in structure to low density lipoprotein (LDL), but has
a specific apolipoprotein, called apolipoprotein(a) [apo(a)],
linked by a disulfide bond to apolipoprotein B100 of LDL (1).
Apolipoprotein(a) is characterized by a high degree of genetic
polymorphism, with many isoforms in plasma (2,3). Lipopro-
tein(a) plasma concentrations are largely determined by
apo(a) gene, and they are inversely related to the molecular
weight (MW) of apo(a) isoforms (4). Many studies have shown
that Lp(a) levels are closely associated with premature coro-
nary heart disease (CHD) (5–12). Studies on the association
between Lp(a) levels and CHD in older persons have reported
quite contradictory results (5–7,13,14). Some investigations
have suggested the importance of apo(a) polymorphism as a
predictor of CHD (15–17), especially when apo(a) polymor-
phism is studied by high resolution methods (18–20). However,
no specific studies have investigated apo(a) phenotypes as
predictors of age of onset of CHD. Therefore, we analyzed the
behavior of Lp(a) levels and apo(a) phenotypes in relation to
the age of onset of CHD in patients, grouped according to
their age of CHD onset.
Methods
Subjects. A total of 335 patients with CHD (295 men; 40
women; mean age: 52.0 6 7.3 years) were consecutively
recruited from among patients attending the outpatients’ de-
partment of the Division of Cardiology. The criterion for
inclusion was an established CHD with a clinical onset 1 to 6
months before the recruitment. To avoid variation in Lp(a)
levels caused by acute events, we enrolled the patients at least
1 month after the acute cardiovascular event. However, all
patients were enrolled within 6 months from the clinical onset
of CHD. The mean time elapsed between the clinical onset of
CHD and the enrollment was 2.1 6 1.6 months. Coronary
heart disease was defined as a documented myocardial infarc-
tion (diagnosed by elevation of cardiac enzyme levels and
diagnostic change on their electrocardiogram); coronary artery
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bypass grafting or angioplasty, or a history of angina pectoris
together with a positive exercise test and a stenosis of the
lumen .70% in at least one major coronary vessel. Coronary
heart disease patients were receiving nitrates, calcium channel
blocking agents, beta-adrenergic blocking agents, angiotensin-
converting enzyme inhibitors and antiaggregant agents. No
patients received diuretics, digitalis, estrogens, lipid-lowering
drugs or niacin. Diagnosis of diabetes mellitus was done
according to the criteria of the National Diabetes Data Group
(21). Diagnosis of hypertension was done according to WHO/
ISH criteria (22). We also evaluated a family history of
coronary heart disease (first degree relatives with documented
myocardial ischemia or infarction) and smoking habits (as the
percentage of smokers/nonsmokers and as smoking index 5
daily cigarettes 3 years of smoking). Exclusion criteria were:
valvular heart disease, bundle branch block, congestive heart
failure, cardiomyopathy and renal or liver diseases. Patients
were divided into three groups according to their age of onset
of CHD: 50 patients were 44 years old or younger, 152 patients
were aged 45 to 54 years and 133 patients were 55 years old or
older. As control groups, three groups of healthy subjects
matched for age and gender were enrolled from blood donors,
staff hospital and their relatives. In every control subject the
medical history and an exercise stress test excluded the possi-
bility of CHD (19,20,23). All subjects recruited were White
Italians and gave their informed consent to participate in the
study. A part of the database (21.7% of the patients and 60.2%
of the control subjects) was the same as a previous report (20).
Laboratory procedures. Venous blood samples were taken
from all subjects between 9 and 11 AM after fasting for 12 h.
For the quantification of Lp(a) and the characterization of
apo(a) isoforms we used plasma obtained by addition of
ethylenediaminetetraacetic acid and low speed centrifugation
at 4°C for 12 min. Immediately after centrifugation, the plasma
samples were frozen and stored at 280°C. Total cholesterol,
high density lipoprotein (HDL) cholesterol and triglycerides
were enzymatically measured by an automatic analyzer Hitachi
737 (Tokyo, Japan). Low density lipoprotein cholesterol was
calculated by Friedewald’s formula (24), considering the con-
tribution of Lp(a) on LDL levels (25). Lipoprotein(a) plasma
concentrations were determined by a sandwich enzyme-linked
immunosorbent assay method [Macra-Lp(a), SDI, Newark,
Delaware]. To detect apo(a) isoforms, an immunoblotting
technique was used, as previously described (26). Briefly, after
an electrophoretic run performed on 1% sodium dodecyl
sulfate–agarose submarine gel, the proteins separated were
transferred onto a polyvinylidene difluoride membrane (Im-
mobilon P, Millipore, Bedford, Texas), by a capillary blotting
technique. Then, the proteins were tested with a polyclonal
antihuman Lp(a) antiserum from sheep (Immuno AG, Vienna,
Austria). Peroxidase-conjugate rabbit antisheep immuno-
globulins (Dako, Glostrup, Denmark) were used as a second
antibody. At the end, the polyvinylidene difluoride membrane
was immersed in a developing solution. As standards, apo(a)
isoforms F1 5 400 kDa, S1 5 520 kDa, S2 5 580 kDa and S3 5
640 kDa (27) (Immuno AG) were utilized.
Statistical analysis. By using an analysis of covariance, all
data regarding lipid parameters were adjusted for gender, body
mass index (BMI), smoking habits, drug intake and presence of
diabetes, hypertension and menopause. To assess differences
in cholesterol, LDL, HDL and BMI, the Student t test
(comparison between two groups) or analysis of variance
(comparison among three groups) was utilized. Because of the
highly “skewed” distribution of Lp(a) and triglycerides levels,
to compare Lp(a) and triglycerides values the Mann–Whitney
U test (comparison between two groups) or Kruskall–Wallis
test (comparison among three groups) was used. The Pearson
chi-square test was exploited for frequency comparison, as
apo(a) isoforms, smokers/nonsmokers and so on. The relation-
ship between Lp(a) levels and apo(a) phenotypes was evalu-
ated both by Pearson’s correlation coefficient and analysis of
variance. Stepwise regression analysis was used to predict age
of CHD onset among patients. Gender, diabetes, hyperten-
sion, family history of CHD, smoking index, BMI, Lp(a),
cholesterol, triglycerides, LDL, HDL and apo(a) phenotypes
of patients were tested as potential predictors. A forward
selection procedure was used. The forward selection starts with
an empty model and adds independent variables in order of
their ability to predict the dependent variable (age of onset of
CHD). The criterion for inclusion into the model as an
independent variable is a p value ,0.05, as determined with
the F test. Variables showing a nonnormal distribution were
logarithmically transformed before the analysis to produce
approximately normal distribution. To provide a measure of
the association of high Lp(a) levels and apo(a) phenotypes
with CHD, age-specific odds ratios (ORs) were estimated, and
the results were given as ORs and 95% confidence interval.
Data were presented as means 6 SD, unless otherwise stated.
A probability of p , 0.05 was considered significant.
Results
Table 1 reports the biological and clinical features of
patients and control subjects, stratified by age. Among the
patient groups, no differences in common cardiovascular risk
factors were observed. The percentage of male, diabetic and
hypertensive subjects significantly increased together with the
age of the onset of CHD. Although Lp(a) levels were higher in
younger patients, among the three patient groups the differ-
ence in Lp(a) levels did not achieve statistical significance.
Abbreviations and Acronyms
apo(a) 5 apolipoprotein(a)
BMI 5 body mass index
CHD 5 coronary heart disease
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
Lp(a) 5 lipoprotein(a)
MW 5 molecular weight
OR 5 odds ratio
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Moreover, no differences in the percentage of subjects with
Lp(a) levels .30 mg/dl were observed. However, each patients
group showed Lp(a) levels and a percentage of subjects with
Lp(a) levels .30 mg/dl higher than age-matched control
subjects. We have also evaluated the percentages of subjects
with Lp(a) levels .50 or 70 mg/dl, but no differences were
found.
Analysis of apo(a) polymorphism. Out of the 705 subjects
recruited, we identified 30 different apo(a) isoforms with
apparent MW varying from 280 to 835 kDa. The detection
method gave good sensitivity, specificity and reproducibility, as
previously described (26,28). Among the patients, 166 (49.5%)
were heterozygotes (29 in the group of patients younger than
45 years; 82 in that of patients aged 45 to 54 years; 55 in that
of patients 55 years old or older), 169 (50.5%) showed only one
apo(a) isoform (21 in the group of patients younger than 45
years; 70 in that of patients aged 45 to 54 years; 78 in that of
patients 55 years old or older) and none had the so-called
“null-phenotype” (no bands detectable by immunoblotting).
Among the control subjects, 177 (47.9%) were heterozygotes
(25 in the group of control subjects younger than 45 years; 82
in that of control subjects aged 45 to 54 years; 70 in that of
Table 1. Biological and Clinical Characteristics of Patients and Control Subjects Stratified by Age
Patients
p, 45 Years 45 to 54 years . 54 Years
n 50 152 133
Age (yr) 40.6 6 3.4 49.6 6 2.7 59.1 6 3.9 , 0.001
Age range (yr) 32 to 44 45 to 54 55 to 75
Gender (M/F) 49/1 134/18 112/21 , 0.05
Family history of CHD 56.0% 50.6% 42.1% NS
Diabetes 10.0% 20.3% 27.8% , 0.05
Duration (yr) 8.2 6 5.3 8.2 6 6.0 6.6 6 7.8 NS
Hypertension 14.0% 32.8% 45.8% , 0.001
Duration (yr) 5.1 6 3.6 7.4 6 4.4 5.8 6 5.2 NS
Smokers 74.0%* 66.4%* 60.9%* NS
Smoking index 446.1 6 397.5* 422.8 6 405.4* 460.1 6 510.5* NS
BMI 26.6 6 4.3* 25.5 6 3.1 25.2 6 3.1 NS
Triglycerides (mmol/liter) 1.8 6 0.7† 1.7 6 0.6* 1.7 6 0.7 NS
Cholesterol (mmol/liter) 5.8 6 1.4* 5.9 6 1.1* 5.9 6 1.2* NS
LDL (mmol/liter) 3.8 6 1.2* 3.8 6 0.9* 3.9 6 1.0* NS
HDL (mmol/liter) 1.1 6 0.2 1.1 6 0.2 1.1 6 0.2 NS
Lp(a) (mg/dl)
Mean 29.8 6 23.9 28.9 6 22.3 27.9 6 22.9
Median 27.2* 24.0* 18.5* NS
Range 0.5 to 88.5 0.5 to 92.5 0.5 to 97
Percentage of subjects with Lp(a) . 30 mg/dl 42.0%* 33.5%* 36.8%* NS
Control Subjects
p,45 Years 45 to 54 years .54 years
n 69 158 143
Age (yr) 40.5 6 3.6 49.7 6 2.8 59.0 6 3.9 , 0.001
Age range (yr) 32 to 44 45 to 54 55 to 75
Gender (M/F) 68/1 139/19 120/23 , 0.05
Family history of CHD 13.0% 28.4% 24.2% , 0.05
Smokers 26.0% 30.3% 25.0% NS
Smoking index 98.9 6 123.6 166.3 6 297.5 157.2 6 300.5 , 0.001
BMI 22.5 6 3.6 23.9 6 3.1 24.4 6 3.6 , 0.001
Triglycerides (mmol/liter) 1.4 6 0.4 1.4 6 0.5 1.5 6 0.8 NS
Cholesterol (mmol/liter) 4.8 6 0.6 5.1 6 1.0 5.3 6 1.1 , 0.05
LDL (mmol/liter) 2.9 6 0.7 3.1 6 0.8 3.2 6 1.0 NS
HDL (mmol/liter) 1.3 6 0.2 1.2 6 0.2 1.2 6 0.3 NS
Lp(a) (mg/dl)
Mean 15.0 6 16.9 14.5 6 15.9 14.0 6 16.5 NS
Median 8.5 7.5 8.0
Range 0 to 84 0 to 80 0 to 83.5
Percentage of subjects with Lp(a) . 30 mg/dl 14.0% 13.9% 13.2% NS
*p , 0.001 (vs. age-matched control subjects). †p , 0.05 (vs. age-matched control subjects). ‡p , 0.01 (vs.
age-matched control subjects). BMI 5 body mass index; CHD 5 coronary heart disease; HDI 5 high density lipoprotein;
LDI 5 low density lipoprotein; Lp(a) 5lipoprotein(a).
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control subjects 55 years old or older), 185 (50.0%) showed
only one apo(a) isoform (42 in the group of control subjects
younger than 45 years; 73 in that of control subjects 45 to 54
years old; 70 in that of control subjects 55 years old or older)
and 8 (2.1%) showed the “null-phenotype” (2, 3 and 3,
respectively). As done in previous studies (19,20,28–30), we
used a cutoff between 640 and 655 kDa to divide apo(a)
isoforms of low MW (280-400-430-445-460-490-505-520-535-
550-565-580-595-610-625-640 kDa) and high MW (655-670-
685-700-715-730-745-760-775-790-805-820-835 kDa). This cut-
off seems to discriminate well apo(a) isoforms associated with
high cardiovascular risk (19,20). In every patient group the
percentage of apo(a) isoforms of low MW was greater than
that of isoforms of high MW. In particular, the percentage of
apo(a) isoforms of low MW was 75.8% in the group of patients
younger than 45 years, 69.6% in patients aged 45 to 54 years
and 58.0% in patients 55 years old or older. On the contrary, in
every control group the percentage of apo(a) isoforms of high
MW was higher than that of isoforms of low MW. In particular,
the percentage of apo(a) isoform of high MW was 72.2% in the
group of control subjects younger than 45 years, 76.1% in
control subjects aged 45 to 54 years and 76.3% in control
subjects 55 years old or older. Among the three patient groups,
the difference in the percentages of apo(a) isoforms of low and
high MW was significant (chi-square 5 7.818; df 5 2; p ,
0.02). In addition, the difference in apo(a) isoforms between
each patient group and age-matched control group was highly
statistically significant (p , 0.001). In our study population
Lp(a) levels were inversely related to apo(a) isoforms MW in
both patients (r 5 20.289966; p 5 0.000000) and control
subjects (r 5 20.295531; p 5 0.000553). This analysis was
performed between each apo(a) isoform (expressed as a MW)
and Lp(a) levels log-transformed. In subjects showing two
electrophoretic bands, the band with lower MW was consid-
ered for the expression of the phenotype, because the band
with lower MW was well correlated with Lp(a) in double-band
phenotype (31). Analysis of variance shows that apo(a) phe-
notypes explained 25% of the variability in Lp(a) levels in
control subjects and 33% in patients.
Analysis of apo(a) phenotypes. Table 2 reports number
and percentage of subjects with several apo(a) phenotypes in
groups of patients and control subjects, stratified by age. First
of all, we divided subjects of each group into two subgroups:
subjects with at least one apo(a) isoform of low MW (low
phenotypes) and subjects with only apo(a) isoforms of high
MW (high phenotypes). In each patient group the percentage
of subjects with low phenotypes is higher than the percentage
of subjects with high phenotypes. On the contrary, in each
control group subjects with high phenotypes are more preva-
lent. The difference in apo(a) phenotypes between each patient
group and age-matched control group is highly significant (p ,
0.001). Moreover, among the three groups of patients the
difference in apo(a) phenotypes is significant (chi-square 5
8.999; df 5 2; p , 0.02).
Then, subjects with at least one apo(a) isoform were
subdivided into two subgroups: subjects with two apo(a) iso-
forms of low MW and subjects with one apo(a) isoform of low
MW. As shown in Table 2, among CHD patient groups,
whereas no differences in the percentage of subjects with one
apo(a) isoform of low MW were observed, the difference in the
percentage of subjects with two apo(a) isoforms of low MW is
highly significant (chi-square 5 16.372; df 5 2; p , 0.001).
Multivariate analysis. In CHD patients the common car-
diovascular risk factors, including Lp(a) concentration, were
tested as potential predictors of age of CHD onset (dependent
variable) in a stepwise regression analysis. This analysis
showed that only hypertension entered into the model as a
significant independent variable (step 5 1; F value 5 9.563399;
beta 5 0.167084; p 5 0.002153). When apo(a) phenotypes
(presence of two isoforms of low MW; presence of one isoform
of low MW; presence of only isoforms of high MW) were
added to the list of potential predictors, regression analysis
showed that apo(a) phenotypes (step 5 1; F value 5 37.53338;
beta 5 20.325534; p 5 0.000000), male gender (step 5 2; F
Table 2. Number and Percentage of Several Apolipoprotein(a) Phenotypes Found in Patients and Control Subjects Stratified by Age
apo(a) Phenotypes
Patients
p
, 45 Years
(n 5 50)
45 to 54 Years
(n 5 152)
. 54 Years
(n 5 133)
Subjects with at least one apo(a) isoform of low MW 44 (88.0%)* 131 (86.2%)* 98 (73.7%)* , 0.02
Subjects with two apo(a) isoforms of low MW 16 (32.0%)* 32 (21.1%)* 11 (8.3%) , 0.001
Subjects with one apo(a) isoform of low MW 28 (56.0%)† 99 (65.1%)* 87 (65.4%)* NS
Subjects with only apo(a) isoforms of high MW 6 (12.0%)* 21 (13.8%)* 35 (26.3%)* , 0.02
apo(a) Phenotypes
Control Subjects
p
, 45 Years
(n 5 69)
45 to 54 Years
(n 5 158)
. 54 Years
(n 5 143)
Subjects with at least one apo(a) isoform of low MW 23 (33.2%) 51 (32.3%) 48 (33.6%) NS
Subjects with two apo(a) isoforms of low MW 3 (4.3%) 6 (3.8%) 2 (1.4%) NS
Subjects with one apo(a) isoform of low MW 20 (28.9%) 45 (28.5%) 46 (32.2%) NS
Subjects with only apo(a) isoforms of high MW 46 (66.8%) 107 (76.7%) 95 (66.4%) NS
*p , 0.001 (vs. age-matched control subjects). †p , 0.05 (vs. age-matched control subjects). apo(a) 5 apolipoprotein(a); MW 5 molecular weight.
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value 5 10.60775; beta 5 20.120434; p 5 0.026956) and
hypertension (step 5 3; F value 5 4.89960; beta 5 0.119076;
p 5 0.027515) are independent variables predicting age of
onset of CHD.
Age-specific ORs of high Lp(a) levels and apo(a) pheno-
types. Table 3 reports age-specific ORs of high Lp(a) levels
and low apo(a) phenotypes for CHD. High Lp(a) levels
significantly increased the risk for CHD in every age, even if
Lp(a) levels did not seem to show important differences in
ORs in relation to age of CHD onset. On the contrary, the
age-specific ORs of low apo(a) phenotypes declined with the
age; in particular low apo(a) phenotypes conferred the highest
cardiovascular risk in subjects ,45 years old. Age-specific ORs
for the presence of two isoforms of low MW and for the
presence of one apo(a) isoform of low MW were also esti-
mated. The age-specific ORs for presence of two isoforms of
low MW/presence of only isoforms of high MW were 40.88
(9.14 to 182.91) in the younger age group, 27.17 (10.10 to
73.09) in the age group of 45 to 54 years and 15.83 (3.33 to
75.18) in the older age group. Therefore, subjects with two
isoforms of low MW have a risk of developing CHD before 45
years 40.88-fold higher than subjets with only isoforms of high
MW. The risk related to this phenotype decline with age. The
age-specific ORs for the presence of one apo(a) isoform of low
MW/presence of only apo(a) isoforms of high MW were 10.73
(3.84 to 29.95) in the younger age group, 11.20 (6.24 to 20.13)
in the age group of 45 to 54 years and 5.13 (3.03 to 8.69) in the
older age group.
Discussion
The present report shows a strong association between
Lp(a) levels and CHD. This finding is in agreement with many
case–control studies (5–8,10,12,15–20,27) and some prospec-
tive studies (9,11,32–34). However, in some of the large-scale
prospective studies no strong association between Lp(a) levels
and CHD has been identified (35–37). Different experimental
designs, different number and characteristics of subjects re-
cruited, ethnical differences, medical treatments (aspirin, beta
carotene, lipid-lowering drugs), lack of standardization of
methods for the determination of Lp(a) levels and different
ways in which plasma samples are handled might at least
partially explain the differences among the studies. Only one
prospective study analyzed both Lp(a) levels and apo(a) phe-
notypes as predictors of CHD (38). In that study Lp(a) levels
appeared a strong independent risk factor for CHD in men,
but apo(a) phenotypes did not (38). This contradictory result
might be explained not only by the relatively small number of
case–control pairs and the high number of apo(a) isoforms
(38) but also by the fact that a cutoff of apo(a) polymorphism
was not used (20).
Lp(a) levels, apo(a) phenotypes and age of onset of CHD.
Lipoprotein(a) levels do not seem to be reliable predictors of
age of onset of CHD. Indeed, several studies documented
elevated Lp(a) levels in patients with premature CHD (5–12),
whereas conflicting results have been reported on the role of
Lp(a) levels in the development of CHD in older persons
(5–7,13,14). In our survey we found significant differences in
Lp(a) levels between each patient group and age-matched
control group; moreover, among patient groups no differences
were observed both in univariate and in multivariate analysis.
When apo(a) phenotypes were analyzed, we observed that
significant differences in the percentage of subjects with only
one apo(a) isoform of low MW exist between each patient
group and age-matched control group; nevertheless, no differ-
ences in the distribution of this phenotype were present among
patient groups. Therefore, Lp(a) levels and the presence of
one apo(a) isoform of low MW have the same behavior in
relation to age of CHD onset. This suggests that subjects with
high Lp(a) levels and one apo(a) isoform of low MW have a
high genetic risk of developing CHD, but for these subjects it
is not possible to predict the age of occurrence. However, the
presence of one apo(a) isoform of low MW appears to be a
genetic risk factor independent of Lp(a) levels. Therefore, in a
primary prevention setting it might be useful to take into
consideration both Lp(a) levels and apo(a) phenotypes to
identify the highest number of subjects with high cardiovascu-
lar risk linked to apo(a) gene. Indeed, if only Lp(a) levels are
considered, subjects with normal Lp(a) levels but near to cutoff
(for example: 15 to 30 mg/dl) usually are not considered at high
risk for CHD. In reality, some of these subjects may have an
isoform of low MW, considering that persons with the same
apo(a) phenotype often show widely diffent Lp(a) levels and
vice versa (4,39). Moreover, to evaluate well the genetic
cardiovascular risk related to apo(a) gene, the study of apo(a)
polymorphism is useful in subjects with genetic or environmen-
tal factors that can affect Lp(a) levels (40). The interesting new
finding of this investigation regards the presence of two apo(a)
isoforms of low MW. Indeed, a strong association between this
apo(a) phenotype and CHD at a young age is present.
Whereas the presence of two isoforms of low MW in control
groups is quite uncommon (4.3% or less), this phenotype has a
high prevalence in CHD patients ,45 years old (32%); in
addition, its prevalence declines significantly with age. The
strong association between the presence of two isoforms of low
MW and CHD at a young age is confirmed by ORs; indeed,
subjects with two isoforms of low MW have a risk of develop-
ing CHD before 45 years 40.88-fold higher than subjects with
only isoforms of high MW. Therefore, the presence of two
apo(a) isoforms of low MW could represent an efficient
discriminator of subjects with high genetic risk for early onset
CHD, in particular of subjects with high genetic risk of
Table 3. Age-Specific Odds Ratios and 95% Confidence Intervals of
High Lipoprotein(a) [Lp(a)] Levels (. 30 mg/dl) and Low
Apolipoprotein(a) [apo(a)] Phenotypes (Presence of at Least One
Isoform of Low Molecular Weight) for Coronary Heart Disease
Age (yr) High Lp(a) Levels Low apo(a) Phenotypes
, 45 4.27 (1.78 to 10.24) 14.62 (5.45 to 39.45)
45 to 54 3.40 (1.94 to 5.96) 13.00 (7.41 to 23.11)
$ 55 3.80 (2.04 to 6.92) 5.54 (3.29 to 9.34)
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developing CHD before 45 years. However, the importance of
apo(a) phenotypes in identifying subjects with high risk for
early CHD is emphasized both by regression analysis and by
ORs for low phenotypes. It is interesting to note that stepwise
regression analysis showed a strong independent correlation
between apo(a) phenotypes and age of CHD onset among
patients recruited. The regression analysis was performed,
including as the dependent variable the age of each patient and
not a categorization of data (for example, in relation to age
groups). Therefore the differences in apo(a) phenotypes found
in univariate analysis among patient groups are not influenced
by the age cutoff points chosen to divide subjects. However, we
used some cutoff points, to permit a clinical interpretation of
results. In particular, a cutoff point (55 years) is helpful to
identify subjects with premature CHD (5,6,9,17); moreover,
among patients with premature CHD, another cutoff point (45
years) was fixed to identify subjects with CHD at a young age.
Apolipoprotein(a) isoforms and atherothrombosis. Obvi-
ously it is important to understand why two apo(a) isoforms of
low MW are more strongly associated with early CHD than the
presence of one apo(a) isoform of low MW. This may be
explained by a possible additional direct role of apo(a) iso-
forms in atherothrombosis independently of corresponding
Lp(a) plasma concentrations. Indeed, recently it has been
hypothesized that different apo(a) isoforms may differ in their
pathogenicity by a mechanism that is independent of corre-
sponding Lp(a) level in plasma (41). In addition, it is generally
accepted that the majority of Lp(a)–substrate interactions are
mediated by the apo(a) component of Lp(a) (42). Finally, a
recent study has shown that apo(a) isoforms may display
polymorphism-linked functional heterogeneity with regard to
cell binding, which may explain the higher association with
cardiovascular risk of small apo(a) isoforms (43). Our study
seems to provide in vivo evidence of these findings. Therefore,
it is reasonable to hypothesize that in subjects with high Lp(a)
levels and both isoforms of low MW, coronary atherosclerosis
may be earlier and more accelerated; moreover, thrombotic
mechanisms due to Lp(a) (44) may be more active. Thus CHD
might occur at a younger age.
Clinical implications. The present study may have impor-
tant clinical implications. Indeed, if our data are confirmed by
larger studies, apo(a) phenotypes could be used together with
Lp(a) levels as powerful markers to assess the genetic risk of
developing CHD at a young age. Indeed, the analysis of apo(a)
polymorphism in subjects with high Lp(a) levels might permit
discriminating subjects with a high genetic risk for CHD (when
one isoform of low MW is present), and those at high risk for
CHD before 45 years (when both isoforms have low MW). This
analysis may have great importance both in patients having
diseases with high cardiovascular risk (diabetes, hypertension,
familial hypercholesterolemia) and in subjects with other car-
diovascular risk factors. Indeed, in these persons, when a high
risk for early onset CHD linked to apo(a) gene is present, more
intensive treatment of modifiable cardiovascular risk factors,
and early and frequent diagnostic checks could be suitable.
Conclusions. The present article reports the first evidence
of a strong independent association of apo(a) phenotypes with
CHD at a young age. Accordingly, apo(a) phenotypes might be
used together with Lp(a) levels as reliable genetic markers in
assessing more precisely the risk of an early onset CHD.
References
1. Scanu AM, Fless GM. Lipoprotein (a). Heterogeneity and biological rele-
vance. J Clin Invest 1990;85:1709–15.
2. Ilyas Kamboh M, Ferrel RE, Kottke BA. Expressed hypervariable polymor-
phism of apolipoprotein(a). Am J Hum Genet 1991;49:1063–74.
3. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34
apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) al-
leles between American blacks and whites. Biochem Biophys Res Commun
1993;191:1192–6.
4. Boerwinkle E, Leffert CC, Lin C, Lackner G, Chiesa G, Hobbs HH.
Apolipoprotein(a) gene accounts for greater than 90% of the variation in
plasma lipoprotein(a) concentration. J Clin Invest 1992;90:52–60.
5. Sunayama S, Daida H, Mokuno H, et al. Lack of increased atherosclerotic
risk due to elevated lipoprotein(a) in women $55 years of age. Circulation
1996;94:1263–8.
6. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM.
Association of levels of lipoprotein(a), plasma lipid and other lipoproteins
with coronary artery disease documented by angiography. Circulation 1986;
74:758–65.
7. Rhoads JJ, Dahlen GH, Berg K, Morton NE, Dannenberg AL. Lp(a)
lipoprotein as a risk factor for myocardial infarction. JAMA 1986;256:
2540–4.
8. Sandkamp M, Funke H, Schulte H, Kolher E, Assmann G. Lipoprotein(a) is
an independent risk factor for myocardial infarction at a young age. Clin
Chem 1990;36:20–3.
9. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a)
and coronary heart disease in men aged 55 years and younger. A prospective
study. JAMA 1996;276:544–8.
10. Genest J, Jenner JL, McNamara JR, et al. Prevalence of lipoprotein(a)
[Lp(a)] excess in coronary artery disease. Am J Cardiol 1991;67:1039–45.
11. Rosengren A, Wihelmsen L, Eriksson E, Risberg B, Wedel H. Lipopro-
tein(a) and coronary heart disease: a prospective case-control study in a
general population sample of middle aged men. BMJ 1990;301:1248–51.
12. Durrington PN, Ishola M, Hunt L, Arrol S, Bhatnagar D. Apolipopro-
teins(a), A1, and B and parental history in men with early onset ischemic
heart disease. Lancet 1988;ii:1070–3.
13. Simons L, Friedlander Y, Simons J, McCallum J. Lipoprotein(a) is not
associated with coronary heart disease in the elderly: a cross-sectional data
from the Dubbo study. Atherosclerosis 1993;99:87–95.
14. Kario K, Matsuo T, Imiya M, et al. Close relation between lipoprotein(a)
levels and atherothrombotic disease in Japanese subjects .75 years of age.
Am J Cardiol 1994;73:1187–90.
15. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a)
concentration and apolipoprotein(a) phenotype to coronary heart disease in
patients with familial hypercholesterolemia. N Engl J Med 1990;322:1494–9.
16. Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for
coronary heart disease. A study in six populations. Arterioscler Thromb
1992;12:1214–26.
17. Parlavecchia M, Pancaldi A, Taramelli R, et al. Evidence that apolipopro-
tein(a) phenotype is a risk factor for coronary artery disease in men ,55
years of age. Am J Cardiol 1994;74:346–51.
18. Kraft HG, Lingenhel A, Kochl S, et al. Apolipoprotein(a) Kringle IV repeat
number predicts risk for coronary heart disease. Arterioscler Thromb Vasc
Biol 1996;16:713–9.
19. Gazzaruso C, Buscaglia P, Garzaniti A, et al. Association of lipoprotein(a)
levels and apolipoprotein(a) phenotypes with coronary heart disease in
patients with essential hypertension. J Hypertens 1997;15:227–35.
20. Gazzaruso C, Garzaniti A, Buscaglia P, et al. Apolipoprotein(a) phenotypes
and their predictive value for coronary heart disease: identification of an
operative cut-off of apolipoprotein(a) polymorphism. J Cardiovasc Risk
1998;5:37–42.
21. National Diabetes Data Group. Classification and diagnosis of diabetes
162 GAZZARUSO ET AL. JACC Vol. 33, No. 1
APO(a) PHENOTYPES AND EARLY CORONARY DISEASE January 1999:157–63
mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039–
57.
22. 1993 Guidelines for the management of mild hypertension: Memorandum from
a WHO/ISH meeting. ISH Hypertension News Special Edition, June 1993:3–16.
23. Falcone C, De Servi S, Poma E, et al. Clinical significance of exercise-
induced silent myocardial ischaemia in patients with coronary artery disease.
J Am Coll Cardiol 1987;9:295–9.
24. Friedewald WT, Levy RI, Fredrikson DS. Estimation of the concentration of
low-density lipoprotein cholesterol in plasma, without ultracentrifuge. Clin
Chem 1972;18:499–502.
25. Li KM, Wilcken DEL, Dudman NPB. Effect of serum lipoprotein(a) on
estimation of low density lipoprotein cholesterol by the Friedewald formula.
Clin Chem 1994;40:571–3.
26. Geroldi D, Bellotti V, Buscaglia P, et al. Characterization of apo(a)
polymorphism by a modified immunoblotting technique in an Italian popu-
lation sample. Clin Chim Acta 1993;221:159–69.
27. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G. Apolipopro-
tein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to
coronary heart disease in a Chinese population: evidence for the role of the
apo(a) gene in coronary heart disease. J Clin Invest 1992;89:1040–6.
28. Gazzaruso C, Buscaglia P, Garzaniti A, et al. Lp(a) plasma concentrations,
apo(a) apolipoprotein(a), polymorphism and family history of coronary
heart disease in patients with essential hypertension. J Cardiovasc Risk
1996;3:191–7.
29. Buscaglia P, Gazzaruso C, Garzaniti A, Bonetti G, Fratino P, Geroldi D.
Lipoprotein(a), apolipoprotein(a), polymorphism and insulin treatment in
type 2 diabetic patients (letter). Diabetes Care 1995;18:1202–3.
30. Gazzaruso C, Bonetti G, Garzaniti A, et al. Increased plasma concentrations
of lipoprotein(a) for every phenotype of apolipoprotein(a) in patients with
chronic renal failure treated by hemodialysis. Nutr Metab Cardiovasc Dis
1996;6:203–10.
31. Kikuchi S, Nakagawa A, Kobayashi K, et al. High degree of genetic
polymorphism in apolipoprotein(a) associated with plasma lipoprotein(a)
levels in Japanese and Chinese populations. Hum Genet 1993;92:537–44.
32. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk
of coronary heart disease in men. The lipid research clinics coronary primary
prevention trial. JAMA 1994;27:999–1003.
33. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson
G, Sigfusson N. Predictive value of apolipoproteins in a prospective survey of
coronary artery disease in men. Am J Cardiol 1992;69:1251–4.
34. Cremer P, Nagel D, Labrot B, et al. Lipoprotein Lp(a) as predictor of
myocardial infarction in comparison to fibrinogen, LDL cholesterol and
other risk factors: results from the prospective Go¨ttingen Risk Incidence and
Prevalence Study (GRIPS). Eur J Clin Invest 1994;24:444–53.
35. Jauhianen M, Koskinen P, Ehnolm C, et al. Lipoprotein(a) and coronary
heart disease risk: a nested case-control study of the Helsinki Heart Study
participants. Atherosclerosis 1991;85:59–67.
36. Alfthan G, Pekkanen J, Jauhainen M, et al. Relation of serum homocysteine
and lipoprotein(a) concentrations to atherosclerotic disease in a prospective
Finnish population based study. Atherosclerosis 1994;106:9–19.
37. Cantin B, Gagnon F, Moorjani S, et al. Is lipoprotein(a) an independent risk
factor for ischemic heart disease in men? The Quebec Cardiovascular Study.
J Am Coll Cardiol 1998;31:519–25.
38. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of
lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in
Stanford Five-City Project Participants. Arterioscler Thromb Vasc Biol
1997;17:239–45.
39. Perombelon YFN, Soutar AK, Knight B. Variation in lipoprotein(a) con-
centration associated with different apolipoprotein(a) alleles. J Clin Invest
1994;93:1481–92.
40. Boerwinkle E. Genetics of plasma lipoprotein(a) concentrations. Curr Opin
Lipidol 1992;3:128–36.
41. Marcovina SM, Albers JJ, Wijsman E, Zhang ZH, Chapman NH, Kennedy
H. Differences in Lp(a) concentrations and apo(a) polymorphs between
black and white Americans. J Lipid Res 1996;37:2569–85.
42. Liu AC, Lawn RM. Vascular interaction of lipoprotein(a). Curr Opin
Lipidol 1994;5:269–73.
43. Kang C, Durlach V, Soulat T, Fournier C, Angles-Cano F. Lipoprotein(a)
isoforms display differences in affinity for plasminogen-like binding to human
mononuclear cells. Arterioscler Thromb Vasc Biol 1997;17:2036–43.
44. Simon DI, Ezratty AM, Loscalzo J. Lipoprotein(a) and atherothrombosis.
Curr Opin Cardiol 1993;8:814–20.
163JACC Vol. 33, No. 1 GAZZARUSO ET AL.
January 1999:157–63 APO(a) PHENOTYPES AND EARLY CORONARY DISEASE
